The Castration Resistant Prostate Cancer Drug market is a subset of the larger Prostate Cancer Drug market. It is composed of drugs that are used to treat prostate cancer that has become resistant to hormone therapy, also known as androgen deprivation therapy. These drugs are used to reduce the levels of testosterone and other hormones that can fuel the growth of prostate cancer cells. Commonly used drugs in this market include abiraterone acetate, enzalutamide, and apalutamide. The Castration Resistant Prostate Cancer Drug market is highly competitive, with many companies offering their own versions of these drugs. Some of the major players in this market include Astellas Pharma, Janssen Pharmaceuticals, Pfizer, Sanofi, and Bayer. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
